Aspira Women’s Health (NASDAQ:AWH) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners reduced their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 6.8 %

Aspira Women’s Health stock opened at $0.84 on Wednesday. The firm has a market capitalization of $13.52 million, a PE ratio of -0.58 and a beta of 1.48. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $6.01. The firm’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.95.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same quarter in the prior year, the company earned ($0.28) earnings per share. On average, research analysts expect that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.73% of Aspira Women’s Health worth $732,000 as of its most recent SEC filing. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.